Cyamemazine decreases ethanol intake in rats and convulsions during ethanol withdrawal syndrome in mice

Autor: Elisabeth Legrand, Françoise d’Alche-Birée, Martine Daoust, Mickaël Naassila
Přispěvatelé: Université de Picardie Jules Verne (UPJV), Naassila, Mickael
Jazyk: angličtina
Rok vydání: 1998
Předmět:
Male
medicine.medical_treatment
Alcohol
MESH: Alcohol Deterrents
MESH: Rats
Sprague-Dawley
Pharmacology
Weight Gain
MESH: Eating
Rats
Sprague-Dawley
Eating
Mice
chemistry.chemical_compound
0302 clinical medicine
Phenothiazines
Medicine
MESH: Animals
Lorazepam
MESH: Seizures
MESH: Motor Activity
MESH: Lorazepam
Substance Withdrawal Syndrome
3. Good health
Acamprosate
Toxicity
MESH: Weight Gain
[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
Antipsychotic Agents
medicine.drug
MESH: Ethanol
Alcohol Drinking
MESH: Rats
MESH: Substance Withdrawal Syndrome
Motor Activity
Cyamemazine
03 medical and health sciences
Seizures
MESH: Phenothiazines
Animals
[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]
MESH: Mice
Ethanol
business.industry
Alcohol dependence
Central Nervous System Depressants
MESH: Male
Rats
030227 psychiatry
MESH: Anti-Anxiety Agents
Anticonvulsant
Anti-Anxiety Agents
chemistry
MESH: Antipsychotic Agents
MESH: Central Nervous System Depressants
business
030217 neurology & neurosurgery
MESH: Alcohol Drinking
Alcohol Deterrents
Zdroj: Psychopharmacology
Psychopharmacology, Springer Verlag, 1998, 140 (4), pp.421-8
Psychopharmacology, 1998, 140 (4), pp.421-8
ISSN: 0033-3158
1432-2072
Popis: International audience; The effect of cyamemazine a dopamine D2 receptor antagonist on voluntary ethanol consumption in rats and on ethanol withdrawal in mice was examined. Male Sprague-Dawley rats were tested in a free choice (water and 10% ethanol) experiment and consumed 5 g/kg ethanol daily. Rats were treated daily IP with cyamemazine (0.5, 1, or 2 mg/kg) or acamprosate (100 mg/kg) during 2 weeks. Both acamprosate and 1 mg/kg cyamemazine significantly decreased ethanol intake by 45% without affecting either fluid or food intake. The lowest dose of cyamemazine had no effect on alcohol intake but increased food intake. The highest dose had no effect on any variables. During the post-treatment period, only 1 mg/kg cyamemazine decreased both ethanol and fluid intakes. Mice were made dependent on alcohol using a chocolate fluid diet containing increasing concentrations of alcohol and withdrawn after 9 days. Mice were treated with cyamemazine (1 or 0.5 mg/kg, respectively) or with the same doses of lorazepam acutely on the day of withdrawal or chronically (during alcohol treatment). Both chronic and acute cyamemazine and lorazepam treatments decreased convulsions during ethanol withdrawal. Both acute treatments decreased locomotor activity in control and alcohol dependent mice. Chronic treatment had no effect on locomotor activity. We suggest that cyamemazine could reduce alcohol consumption by antagonizing the activation of the dopaminergic pathways during the induction of alcohol dependence. The action of cyamemazine on 5-HT3 receptors could also explain its effect on alcohol convulsions during withdrawal convulsions.
Databáze: OpenAIRE
Externí odkaz: